Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 11/20 | 0.76 |
| ▸ | NPY1R | P25929 | 3/20 | 0.36 |
| ▸ | MMP1 | P03956 | 4/20 | 0.35 |
| ▸ | MMP3 | P08254 | 4/20 | 0.35 |
| ▸ | MMP9 | P14780 | 3/20 | 0.35 |
| ▸ | CCKBR | P32239 | 1/20 | 0.34 |
| ▸ | NPY2R | P49146 | 1/20 | 0.33 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5249061 | 1.00 | GHSR (0.76) | GHSRNPY1RMMP1MMP3MMP9 | |
| SCHEMBL5246834 | 1.00 | GHSR (0.76) | GHSRNPY1RMMP1MMP3MMP9 | |
| SCHEMBL6213082 | 1.00 | GHSR (0.76) | GHSRNPY1RMMP1MMP3MMP9 | |
| SCHEMBL5246828 | 1.00 | GHSR (0.76) | GHSRNPY1RMMP1MMP3MMP9 | |
| Hydrochloric Acid SCHEMBL5249487 | 0.99 | GHSR (0.75) | GHSRNPY1RMMP1MMP3MMP9 | |
| Hydrochloric Acid SCHEMBL5248090 | 0.99 | GHSR (0.75) | GHSRNPY1RMMP1MMP3MMP9 | |
| Hydrochloric Acid SCHEMBL5248096 | 0.99 | GHSR (0.75) | GHSRNPY1RMMP1MMP3MMP9 | |
| SCHEMBL7669620 | 0.95 | GHSR (0.79) | GHSRCCKBR | |
| SCHEMBL7669621 | 0.95 | GHSR (0.79) | GHSRCCKBR | |
| SCHEMBL19469271 | 0.95 | GHSR (0.79) | GHSRCCKBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150099709-A1 | GHRELIN RECEPTOR AGONISTS FOR THE TREATMENT OF ACHLORHYDRIA | RAQUALIA PHARMA INC. (JP) | 2015-04-09 | — | — | US | claimed |
| EP-2854810-A1 | GHRELIN RECEPTOR AGONISTS FOR THE TREATMENT OF ACHLORHYDRIA | RaQualia Pharma Inc (JP) | 2015-04-08 | — | — | EP | claimed |
| WO-2013175805-A1 | GHRELIN RECEPTOR AGONISTS FOR THE TREATMENT OF ACHLORHYDRIA | RAQUALIA PHARMA INC. (JP) | 2013-11-28 | — | — | WO | claimed |
| EP-0869968-B1 | GROWTH-HORMONE SECRETAGOGUES | PFIZER (US) | 2007-05-02 | — | — | EP | claimed |
| US-20020049196-A1 | Growth-hormone secretagogues | RAQUALIA PHARMA INC. (JP) | 2002-04-25 | — | — | US | claimed |
| US-6107306-A | OSTEOPOROSIS | PFIZER INC. (US) | 2000-08-22 | — | — | US | claimed |
| EP-0869968-A1 | GROWTH-HORMONE SECRETAGOGUES | PFIZER INC. (US) | 1998-10-14 | — | — | EP | claimed |
| WO-1997024369-A1 | GROWTH-HORMONE SECRETAGOGUES | PFIZER INC. (US) | 1997-07-10 | — | — | WO | claimed |
| US-20210179613-A1 | GHRELIN RECEPTOR AGONIST FOR TREATMENT OF CACHEXIA | RAQUALIA PHARMA INC. (JP) | 2021-06-17 | — | — | US | disclosed |
| US-10975070-B2 | Ghrelin receptor agonist for treatment of cachexia | RAQUALIA PHARMA INC. (JP) | 2021-04-13 | — | — | US | disclosed |
| US-20150099709-A1 | GHRELIN RECEPTOR AGONISTS FOR THE TREATMENT OF ACHLORHYDRIA | RAQUALIA PHARMA INC. (JP) | 2015-04-09 | — | — | US | disclosed |
| EP-2854810-A1 | GHRELIN RECEPTOR AGONISTS FOR THE TREATMENT OF ACHLORHYDRIA | RaQualia Pharma Inc (JP) | 2015-04-08 | — | — | EP | disclosed |
| WO-2013175805-A1 | GHRELIN RECEPTOR AGONISTS FOR THE TREATMENT OF ACHLORHYDRIA | RAQUALIA PHARMA INC. (JP) | 2013-11-28 | — | — | WO | disclosed |
| EP-2540721-A1 | GHRELIN RECEPTOR AGONIST FOR TREATMENT OF DYSCRASIA | RaQualia Pharma Inc (JP) | 2013-01-02 | — | — | EP | disclosed |
| US-6313140-B1 | ADMINISTERING TO A HUMAN OR OTHER ANIMAL PYRAZOLOPYRIMIDINE DERIVATIVE FOR PROPHYLAXIS OR THERAPY OF DISEASE OR CONDITION WHICH MAY BE TREATED OR PREVENTED BY GROWTH HORMONE | PFIZER INC. | 2001-11-06 | — | — | US | disclosed |
| US-6306875-B1 | ADMINISTERING GROWTH HORMONES DIPEPTIDE COMPOUNDS WHICH ARE GROWTH HORMONE SECRETAGOGUES AND ARE USEFUL FOR THE TREATMENT AND PREVENTION OF OSTEOPOROSIS. | PFIZER INC. | 2001-10-23 | — | — | US | disclosed |
| US-6278000-B1 | INCREASE LEVEL OF ENDOGENOUS GROWTH HORMONE; USEFUL IN THERAPY AND PROPHYLAXIS OF OSTEOPOROSIS, CONGESTIVE HEART FAILURE, FRAILTY ASSOCIATED WITH AGING AND OBESITY, ACCELERATING BONE FRACTURE REPAIR | PFIZER INC. | 2001-08-21 | — | — | US | disclosed |
| US-6124264-A | GROWTH HORMONE SECRETAGOGUE IN A HUMAN OR OTHER ANIMAL TO TREAT OSTEOPOROSIS, CONGESTIVE HEART FAILURE, AGING, OBESITY; BONE AND WOUND HEALING AGENTS | PFIZER INC. (US) | 2000-09-26 | — | — | US | disclosed |
| US-6110932-A | INCREASE THE LEVEL OF ENDOGENOUS GROWTH HORMONE FOR THE TREATMENT AND PREVENTION OF OSTEOPOROSIS, CONGESTIVE HEART FAILURE, FRAILTY ASSOCIATED WITH AGING, OBESITY; ACCELERATING BONE FRACTURE REPAIR, ACCELERATING WOUND HEALING | PFIZER INC. (US) | 2000-08-29 | — | — | US | disclosed |
| US-6107306-A | OSTEOPOROSIS | PFIZER INC. (US) | 2000-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099709-A1 | GHRELIN RECEPTOR AGONISTS FOR THE TREATMENT OF ACHLORHYDRIA | GIPR, GHSR, GLP1R | GHSR 2/4885NPY1R 33/4885MMP1 3574/4885 |
| US-10975070-B2 | Ghrelin receptor agonist for treatment of cachexia | GIPR, GCGR, GHSR | GHSR 3/4885NPY1R 52/4885MMP1 3914/4885 |
| US-20020049196-A1 | Growth-hormone secretagogues | GHSR, GHRHR, IGFBP6 | GHSR 1/4885NPY1R 41/4885MMP1 980/4885 |
| US-20210179613-A1 | GHRELIN RECEPTOR AGONIST FOR TREATMENT OF CACHEXIA | GIPR, GCGR, GHSR | GHSR 3/4885NPY1R 52/4885MMP1 3914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.